Enfermedad pulmonar intersticial asociada a esclerosis sistémica (EPI-ES)

 

Effects of nintedanib on circulating biomarkers in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Assassi S et al.

 

Acceder

 

“Effective lung age” in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in the SENSCIS trial

Maher TM et al.

 

Acceder

 

Baseline characteristics of patients with improvement or progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) during the SENSCIS trial

Hoffmann-Vold AM et al.
 

Acceder

 

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) and risk factors for rapid decline in forced vital capacity: further analyses of the SENSCIS trial

Khanna D et al.
 

Acceder

 

Continued treatment with nintedanib in patients with limited cutaneous systemic sclerosis (lcSSc) and interstitial lung disease (ILD)

Allanore Y et al.

 

Acceder

 

 

SC-ES-09814